Leading Longevity Researcher Nir Barzilai Aims to Conquer Aging Biology
Translated & summarized from Globes by baba
Professor Nir Barzilai, a leading aging researcher, believes aging is a biological process that causes disease and is exploring ways to slow it down. His research on centenarians suggests a genetic component to healthy aging, and he is investigating drugs like metformin and GLP-1 agonists as potential interventions to extend healthy lifespan.
The story in 5 lines · by baba
- Aging is a biological process that causes disease, not the other way around.
- Centenarians show a remarkable ability to avoid illness until late in life.
- Genetics play a significant role in healthy aging and longevity.
- Drugs like metformin and GLP-1 agonists may slow aging and prevent disease.
- Healthy aging can reduce healthcare costs and improve quality of life.
Professor Nir Barzilai, a world-renowned aging researcher and head of the Albert Einstein Institute for Aging Research, is dedicated to understanding and potentially reversing the biological processes of aging. His fascination began in childhood, observing the stark contrast between his active grandfather at 67 and his frail appearance. This early observation fueled a lifelong pursuit to understand why some age gracefully while others decline rapidly.
Barzilai's research centers on the revolutionary idea that aging itself is a biological process that drives age-related diseases, rather than being a consequence of them. He highlights studies on centenarians, particularly a cohort of 850 Ashkenazi Jews, who exhibit remarkable health throughout their lives, with illness often appearing only shortly before death. This suggests a genetic or biological mechanism that actively prevents or delays disease, independent of lifestyle choices.
His work indicates that children of centenarians have significantly lower mortality and morbidity rates, suggesting a heritable component to longevity. Barzilai also points out the economic benefits of healthy aging, noting that centenarians incur lower healthcare costs in their final years compared to those who die younger. He is exploring interventions like metformin and GLP-1 agonists, which show promise in slowing aging and preventing diseases.
Barzilai is also developing a "biological clock" to accurately measure the effects of aging interventions and is seeking funding for a large-scale metformin trial. He believes that by understanding and manipulating the biology of aging, humanity could potentially extend healthy lifespan by decades, challenging the biblical notion of a 120-year limit.